Multiple antioxidants and L-arginine modulate inflammation and dyslipidemia in chronic renal failure rats

Renal Failure

Volumn 32, Issue 2, 2010, Pages 203-213

  Korish, Aida A ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Antioxidants; Chronic renal failure; Dyslipidemia; Inflammatory cytokines; L arginine

Indexed keywords

ALPHA TOCOPHEROL; ARGININE; ASCORBIC ACID; CARNITINE; CATECHIN; CHOLESTEROL; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; NITRATE; NITRITE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DYSLIPIDEMIA; INFLAMMATION; KIDNEY FUNCTION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

ANALYSIS OF VARIANCE; ANIMALS; ANTIOXIDANTS; ARGININE; CYTOKINES; DYSLIPIDEMIAS; ENZYME-LINKED IMMUNOSORBENT ASSAY; INFLAMMATION; INFLAMMATION MEDIATORS; INTERCELLULAR ADHESION MOLECULE-1; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; MALE; NITRIC OXIDE; RATS; RATS, WISTAR;

EID: 77749279746     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/08860221003592820     Document Type: Article

References (101)

1. Ignarro LJ, Wei L. Visiting professorial lecture: Nitric oxide in the regulation of vascular function: A historical overview. J Card Surg. 2002;17(4):301-306.
2. Gornik HL, Creager MA. Arginine and endothelial and vascular health. J Nutr. 2004;134 (Suppl. 10):2880S-2887S.
3. Levillain O, Marescau B, de Deyn PP. Guanidino compound metabolism in rats subjected to 20% to 90% nephrectomy. Kidney Int. 1995 Feb; 47(2):464-472.
4. Hostetter TH, Olson JL, Rennke HG, Venkatachalam MA, Brenner BM. Hyperfiltration in remnant nephrons: A potentially adverse response to renal ablation. Am J Physiol. 1981;241:F85-F93.
5. Matasumuto M, Kishikawa H, Mori A. Guanidino compounds in the sera of uremic patients and in the sera of and brain of experimental rabbits. Biochem Med. 1978;6:161-168.
6. Mendoza MG, Castillo-Henkel C, Medina-Santillan R, et al. Kidney damage after renal ablation is worsened in endothe-lial nitric oxide synthase -/- mice and improved by combined administration of L-arginine and antioxidants. Nephrology (Carlton). 2008 Jun; 13(3):218-227.
7. Baylis C. Nitric oxide deficiency in chronic kidney disease. Am J Physiol. 2008;294:F1-F9.
8. Bonomini M, Sirolli V, Di Pietro N, Pandolfi A. Reduced nitric oxide bioavailability in chronic renal failure: A new factor of progression? G Ital Nefrol. 2008;25(3):306-316.
9. Benchetrit S. Early endothelial dysfunction following renal mass reduction in rats. Eur J Clinc Invest. 2003;33(1):26-33.
10. Aiello S, Noris M, Remuzzi G. Nitric oxide synthesis and L-arginine in uremia. Miner Electrolyte Metab. 1997;23(3-6):151-156.
11. Nathan C, Xie QW. Regulation of biosynthesis of nitricoxide. J Biol Chem. 1994;269(19):13725-13728.
12. Taylor BS, Geller DA. Molecular regulation of the human inducible nitric oxide synthase (iNOS) gene. Shock. 2000;13(6):413-424.
13. Rawlingson A, Greenacre SA, Brain SD. Functional significance of iNOS induction, neutrophil accumulation and protein nitration in the thermally injured rat cutaneous microvasculature. Am J Pathol. 2003;162(4):1373- 1380.
14. Lortie MJ, Ishizuka S, Schwartz D, Blantz RC. Bioactive products of arginine in sepsis: Tissue and plasma composition after LPS and iNOS blockade. Am J Physiol Cell Physiol. 2000;278:C1191-C1199.
15. Yamamizu K, Shinozaki K, Ayajiki K, Gemba M, Okamura T. Oral administration of both tetrahydrobiopterin and L-arginine prevents endothelial dysfunction in rats with chronic renal failure. J Cardiovasc Pharmacol. 2007;49(3):131-139.
16. Nieves C Jr, Langkamp-Henken B. Arginine and immunity: A unique perspective. Biomed Pharmacother. 2002;56:471-482.
17. Barbul A, Lazarou SA, Efron DT, Wasserkrug HL, Efron G. Arginine enhances wound healing and lymphocyte immune responses in humans. Surgery. 1990;108:331-336.
18. Cui XL, Iwasa M, Iwasa Y, Ogoshi S. Arginine-supple-mented diet decreases expression of inflammatory cytokines and improves survival in burned rats. J Parenter Enteral Nutr. 2000;24:89-96.
19. Canaud B, Cristol JP, Morena M, Leray-Moragues H. Imbalance of oxidants and antioxidants in hemodialysis patients. Blood Purif. 1999;17:99-106.
20. Witko-Sarsat V, Friedlander M, Capeillere-Blandin C. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int. 1996;49:1304-1313.
21. Himmelfarb J, Stenvinkel P, Ikizler TA. The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int. 2002;62:1524-1538.
22. Descamps-Latscha B, Drueke T, Witko-Sarsat V. Dialysis-induced oxidative stress: Biological aspects, clinical consequences, and therapy. Semin Dial. 2001;14:193-199.
23. Bellinghieri G, Santoro D, Calvani M, Mallamace A, Savica V. Carnitine and hemodialysis. Am J Kidney Dis. 2003:41 (Suppl. 1):S116-S122.
24. Gloper TA, Wolfson M, Ahmed S. Multicenter trial of L-carnitine in maintenance hemodialysis patients, 1: Carnitine concentration and lipid effects. Kidney Int. 1990;38:904-911.
25. Guarnieri G, Situlin R, Biolo G. Carnitine metabolism in uremia. Am J Kidney Dis. 2001;38:S63-S67.
26. Guarnieri G, Biolo G, Vinci P, Massolino B, Barazzoni R. Advances in carnitine in chronic uremia. J Ren Nutr. 2007 Jan; 17(1):23-29.
27. Matera M, Bellinghieri G, Costantino G, Santoro D, Calvani M, Savica V. History of L-carnitine: Implications for renal disease. J Ren Nutr. 2003 Jan; 13(1):2-14.
28. Lambert JD, Sang S, Yang CS. Biotransformation of green tea polyphenols and the biological activities of those metabolites. Mol Pharm. 2007 Nov-Dec;4(6):819-825.
29. Higdon JV, Frei B. Tea catechins and polyphenols: Health effects, metabolism, and antioxidant functions. Crit Rev Food Sci Nutr. 2003;43:89-143.
30. Yang CS, Hong J, Hou Z, Sang S. Green tea polyphenols: Antioxidative and prooxidative effects. J Nutr. 2004;134:3181S.
31. Oslen JL. Role of heparin as a protective agent following reduction of renal mass. Kidney Int. 1993;44:445-450.
32. Dumont Y, D'Amours M, Lebel M, Lariviere R. Supplementation with a low dose of L-arginine reduces blood pressure and endothelin, 1: Production in hypertensive uraemic rats. Nephrol Dial Transplant. 2001;16:746-754.
33. Choi JH, Rhee SJ. Effect of Vit E on renal dysfunction in chronic cadmium poisoned rats. J Med Food. 2003;6(3):209-215.
34. Yargicoglu P, Yaras N, Agar A. The effect of vitamin E on stress-induced changes in visual evoked potentials (VEP) in rats exposed to different experimental stress models. Acta Ophthalmol. Scand. 2003;81(2):181-187.
35. Mahfouz MM, Kummerow FA. Vitamin C or vitamin B6 supplementation prevents the oxidative stress and decrease of prostacyclin generation in homocysteinemic rats. Int J Biochem Cell Biol. 2004;36(10):1919-1932.
36. Anjaneyulu M, Tirkey N, Chopra K. Attenuation of cyclosporine-induced renal dysfunction by catechin: Possible antioxidant mechanism. Ren Fail. 2003;25(5):691-707.
37. Sener G, Paskalogu H, Alican I. L-carnitine ameliorates oxidative damage due to chronic renal failure in rats. J Cardiovasc Pharmacol. 2004 May; 43(5):698-705.
38. 15N) nitrate in biological fluids. Anal Biochem. 1982;126:131-138.
39. st ed. 1984;1257-1260, 437, 418.
40. Murray RL. Creatinine. In Kaplan A, et al. (eds.). Clinical chemistry. St. Louis, Toronto, Princeton: The C. V. Mosby Co.; 1984:1261-1266, 418.
41. Orsonneau JL, Douet P, Massoubre C, Lustenberger P, Bernard S. An improved pyrogallol red-molybdate method for determining total urinary protein. Clin Chem. 1989;35:2233-2236.
42. Naito HK. Cholesterol. In Kaplan A, et al. (eds.). Clinical chemistry. St. Louis, Toronto, Princeton: The C. V. Mosby Co.; 1984:1149-1206, 437.
43. Buccolo G, David H. Quantitative determination of serum triglycerides by use of enzymes. Clin Chem. 1973;19(5):476-482.
44. Bezerra DG, Pires KMP, Lacerda MD. Amlodipine preserves the glomerular number in spontaneously hypertensive rats. J Cell Mol Med. 2005;9(4):966-971.
45. Chmielewski M, Carrero JJ, Stenvinkel P, Lindholm B. Metabolic abnormalities in chronic kidney disease that contribute to cardiovascular disease, and nutritional initiatives that may diminish the risk. Curr Opin Lipidol. 2009 Feb; 20(1):3-9.
46. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int. 1999;55:648-658.
47. Bevc S, Sabic S, Hojs R. Atherosclerosis in hemodialysis patients - the role of microinflammation. Ren Fail. 2008;30(10):1012-1016.
48. Korish AA, Arafah MM. Catechin combined with vitamins C and E ameliorates insulin resistance (IR) and atherosclerotic changes in aged rats with chronic renal failure (CRF). Archives of Gerontology and Geriatrics. 2008;46:25-39.
49. Massy ZA, Nguyen-Khoa T. Oxidative stress and chronic renal failure: Markers and management. J Nephrol. 2002;15:336-341.
50. Göçmen AY, Sahin E, Koçak H, Tuncer M, Gümüslü S. Levels of asymmetric dimethylarginine, nitric oxide and lipid peroxidation markers in patients with end-stage renal disease having peritoneal dialysis treatment. Clin Biochem. 2008 Jul; 41(10-11):836-840.
51. Huang PL, Huang Z, Mashimo H. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature. 1995;377:239-242.
52. Siani A, Pagana E, Lacone R, Lacoviello L. Blood pressure and metabolic changes during dietary L-arginine supplementation in humans. Am J Hypertens. 2000;13:547-551.
53. El-Mesallamy HO, Abdel Hamid SG, Gad MZ. Oxidative stress and asymmetric dimethylarginine are associated with cardiovascular complications in hemodialysis patients: Improvements by L-arginine intake. Kidney Blood Press Res. 2008;31(3):189-195.
54. Boger RH. Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the "L-arginine paradox" and acts as a novel cardiovascular risk factor. J Nutr. 2004;134 (Suppl. 10):2842S-2847S.
55. Cherla G, Edgar A, Jaimes EA. Role of L-arginine in the pathogenesis and treatment of renal disease. J Nutr. 2004;134 (Suppl. 10):2801S-2806S.
56. Rossi NF, Beierwaltes WH. Nitric oxide modulation of ETB receptor induced vasopression release by rat and mouse hypothalamo-neurohypophyseal explants. Am J Physiol Regul Integr Comp. 2006;290:R1208-R1215.
57. Nabokov A, Amann K, Wagner J, Gehlen F, Munter K, Ritz E. Influence of specific and non-specific endothelin receptor antagonists on renal morphology in rats with surgical renal ablation. Nephrol Dial Transplant. 1996;11:514-520.
58. Peters H, Border WA, Noble NA. Tandem antifibrotic action of L-arginine supplementation and low protein diet during the repair phase of experimental glomerulonephritis. Kidney Int. 2000;57:992-1001.
59. Sydow K, Schwedhelm E, Arakawa N. ADMA and oxidative stress are responsible for endothelial dysfunction in hyperho-mocyst(e)inenia: Effects of L-arginine and B vitamins. Cardiovascular Research. 2003;57:244-252.
60. Maines MD. The heme oxygenase system: A regulator of second messenger gases. Ann Rev Pharmacol Toxicol. 1997;37:517-554.
61. Calo LA, Pagnin E, Davis P. Antioxidant effect of L-carnitine and its short chain esters relevance for the protection from oxi-dative stress related cardiovascular damage. Int J Cardiol. 2006;107(1):54-60.
62. Korish AA, Arafah MM. The potential anti-inflammatory effect of tetrahydrobiopetrin administration in renal mass reduction-induced chronic renal failure in rats. Saudi Medical Journal. 2007;28(12):1803-1809.
63. Stonvinkel P, Lindholm B, Heimburger M, Heimburger O. Elevated serum levels of soluble adhesion molecules predicted death in predialysis patients: Association with malnutrition, inflammation and, cardiovascular disease. Nephrol Dial Transplant. 2000;15:1624-1630.
64. Bonomini M, Reale M, Santarelli P, et al. Serum levels of soluble adhesion molecules in chronic renal failure and dialysis patients. Nephron. 1998;79:339-407.
65. Ridker PM, Hemekens CH, Roitman-Johnson B, Stapfer MJ, Allen J. Plasma concentrations of soluble intercellular adhesion molecule 1 and risk of future myocardial infarction in apparently healthy men. Lancet. 1998;351:88-92.
66. Papayianni A, Alexopoulos E, Giamalis P, et al. Circulating levels of ICAM-1, VCAM-1, and MCP-1 are increased in hemodialysis patients: Association within inflammation, dys-lipidaemia, and vascular events. Nephrol Dial Transplant. 2002;17:435-441.
67. Brunini T, Ribeiro AC, Ellory JC, Mann GE. Platelet nitric oxide synthesis in uremia and malnutrition: A role for L-arginine supplementation in vascularprotection? Cardiovascular Research. 2007;73:359-367.
68. Abdullah MS, Wild G, Jacob V, Milford-Ward A, Ryad R, Zanaty M. Cytokines and the malnutrition of chronic renal failure. Miner Electrolyte Metab. 1997;23:237-242.
69. Kubes P, Kusose I, Granger DN. NO donors prevent intregin induced leukocyte adhesion, but not P-selectin-dependent rolling in post ischemic venules. Am J Physiol. 1994;267:H931-H937.
70. Lindemann S, Sharaf M, Spiecker M, Buerke M, Fisch A, Grosser T. NO reduces PMN adhesion to human vascular endothelial cells due to downregulation of ICAM-1mRNA and surface expression. Thromb Res. 2000;97(3):113-123.
71. Kubes P, Suzuki M, Granger DN. Nitric oxide: An endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA. 1991;88(11):4651-4655.
72. Lefer DJ, Jones SP, Girod WG, et al. Leukocyte-endothelial cell interactions in nitric oxide synthase deficient mice. Am J Physiol. 1999;276(6Pt2):H1943-H1950.
73. Kosonen O, Kankaanranta H, Uotila J, Moilanen E. Inhibition by nitric oxide-releasing compounds of E-selectin expression in and neutrophil adhesion to human endothelial cells. Eur J Pharmacol. 2000;394(1):149-156.
74. Maccarrone M, Meloni C, Manca-di-Villahermosa S, et al. Vitamin E suppressed 5-lipoxygenase-mediated oxidative stress in peripheral blood mononuclear cells of hemodialysis patients regardless of administration route. Am J Kidney Dis. 2001;37:964-969.
75. Meagher EA, Barry OP, Lawson JA, Rokach J, Fitzgerald GA. Effects of vitamin E on lipid peroxidaton in healthy persons. JAMA. 2001;285:1178-1182.
76. Costagliola C, Menzione M. Effect of vitamin E on the oxidative state of glutathione in plasma. Clin Physiol Biochem. 1990;8:140-143.
77. Arduini A, Rossi M, Mancinelli G. Effect of L-carnitine and acetyl-L-carnitine on the human erythrocyte membrane stability and deformability. Life Sci. 1990;47:2395-2400.
78. Packer L, Valenza M, Serbinova E. Free radical scavenging is involved in the protective effect of L-propionyl-carnitine against ischemia-reperfusion injury of the heart. Arch Biochem Biophys. 1991;288:533-537.
79. Libera L, Sabbadini R, Renken C. Apoptosis in the skeletal muscle of rats with heart failure is associated with increased serum levels of TNF and sphingosine. J Moll Cell Cardiol. 2001;33:1871-1878.
80. Rodriguez-Segade S, del la Pena C, Paz M. Carnitine concentration in dialysed and undialysed patients with chronic renal insufficiency. Ann Clin Biochem. 1986;23:671-675.
81. El-Metwally TH, Hamed EA, Ahmad AR, Mohamed NA. Dyslipidemia, oxidative stress and cardiac dysfunction in children with chronic renal failure: Effects of L-carnitine supplementation. Ann Saudi Med. 2003 Sep-Oct;23(5):270- 277.
82. Vescovo G, Zennaro R, Sandri M. Apoptosis of skeletal muscle myofibrils and interstitial cells in experimental heart failure. J Mol Cell Cardiol. 1998;30:2449-2459.
83. Savica V, Santo D, Ciolino F. L-carnitine infusions may suppress serum C-reactive protein and improve nutritional status in maintenance hemodialysis patients. J Renal Nutr. 2005;15(2):225-230.
84. Chander V, Singh D, Chopra K. Catechin, a natural antioxidant protects against rhabdomyolysis-induced myoglobinuric acute renal failure. Pharmacological Research. 2003;48:503-509.
85. Jolma P, Koobi P, Kalliovalkama J. Increased calcium intake reduces plasma cholesterol and improves vasorelaxation in experimental renal failure. Am J Physiol Heart Circ Physiol. 2003;285:H1882-H1889.
86. Altaf A, Halim A, Khan DA, Khalid M, Fatima-Tuz-Zuhra SI. Assessment of lipid dysfunction in patients on maintenance hemodialysis. J Ayub Med Coll Abbottabad. 2007 Oct-Dec;19(4):32-36.
87. Creager MA, Cooke JP, Mendelsohn ME, Gallagher SJ. Impaired vasodilatation of forearm resistance vessels in hyper-cholestrolemic humans. J Clin Invest. 1990;86:228-234.
88. Mougenot N, Lesnik P, Ramirez-Gil JF, et al. Effect of oxidation of LDL on the modulation of arterial vasomotor response in vitro. Atherosclerosis. 1997;133:183-192.
89. Vaziri ND, Deng G, Liang K. Hepatic HDL receptor, SR-B1 and Apo A-I expression in chronic renal failure. Nephrol Dial Transplant. 1999 Jun; 14(6):1462-1466.
90. Hasselwander O, McEneny J, McMaster D, et al. HDL composition and HDL antioxidant capacity in patients on regular hemodialysis. Atherosclerosis. 1999 Mar; 143(1):125-133.
91. Kaysen GA, Eiserich JP. The role of oxidative stress-altered lipoprotein structure and function and microinflamation on cardiovascular risk in patients with minor renal dysfunction. J Am Soc Nephrol. 2004;15(3):538-548.
92. Attman PO, Gustafon A. Abnormalities of lipid metabolism. In Giovannetti S (ed.). Nutritional treatment of chronic renal failure. Boston, Mass.: Kluwer Academic Publishers; 1989:294-295.
93. Sokolovic D, Bjelakovic G, Nikolic J, et al. Effect of L-arginine on metabolism of polyamines in rat's brain with extrahepatic cholestasis. Amino Acids. 2009 Mar 13. [Epub ahead of print]
94. Shimizu M, Shirakami Y, Sakai H, et al. (-)-Epigallocat-echin gallate suppresses azoxymethane-induced colonic premalignant lesions in male C57BL/KsJ-db/db mice. Cancer Prev Res (Phila Pa). 2008 Sep; 1(4):298-304.
95. Lee SM, Kim CW, Kim JK, Shin HJ, Baik JH. GCG-rich tea catechins are effective in lowering cholesterol and triglyceride concentrations in hyperlipidemic rats. Lipids. 2008 May; 43(5):419-429.
96. Ramesh E, Elanchezhian R, Sakthivel M, et al. Epigallocat-echin gallate improves serum lipid profile and erythrocyte and cardiac tissue antioxidant parameters in Wistar rats fed an atherogenic diet. Fundam Clin Pharmacol. 2008 Jun; 22(3):275-284.
97. Malaguarnera M, Vacante M, Avitabile T, Malaguarnera M, Cammalleri L, Motta M. L-carnitine supplementation reduces oxidized LDL cholesterol in patients with diabetes. Am J Clin Nutr. 2009;89(1):71-76.
98. Solfrizzi V, Capurso C, Colacicco AM, et al. Efficacy and tolerability of combined treatment with L-carnitine and simvastatin in lowering lipoprotein(a) serum levels in patients with type 2 diabetes mellitus. Atherosclerosis. 2006 Oct; 188(2):455-461.
99. Tribe RM, Poston L. Oxidative stress and lipids in diabetes: A role in endothelium vasodilator dysfunction. Vas Med. 1996;1:195-206.
100. Siani A, Pagano E, Lacone R, Lacoviello L. Blood pressure and metabolic changes during dietary L-arginine supplementation in humans. Am J Hypertens. 2000;13:547-551.
101. Heyland DK, Novak F, Drover JW, Jain M, Su X, Suchner U. Should immunonutrition become routine in critically ill patients? A systematic review of the evidence. JAMA. 2001;286:944-953.